Factor VII

2022 U.S. Coagulation Testing Market Report: Identify and Evaluate Emerging Business Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Research, Managed Care, General Health, Medical Devices, Hospitals, Health Technology, Clinical Trials, Science, Surgery, Biotechnology, Other Science, Health, ACT, Factor VII, Factor XII, Factor, Factor XI, Factor IX, APTT, Protein S, Activated protein C resistance, Thrombin time, Antithrombin, Bleeding time, Protein C, Factor X, Prothrombin time, Consumables, Factor V, Factor VIII, Prekallikrein, Comparison, Factor XIII, Fibrinogen, Marketing, Retail, Vaccine, Fine chemical, Pharmaceutical industry, Plasmin

The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities in the US coagulation testing market during the next five years.
  • The report is available by section, and can be customized to specific information needs and budget.
  • The report explores business and technological trends in the US coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

Global Coagulation Testing Lab and POC Market (2022 to 2026) - Analysis of Current and Emerging Technologies and Their Potential Market Applications - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Health, Medical Devices, Cardiology, ACT, Computer, Factor VII, Factor IX, APTT, Thrombin time, Factor XIII, Coagulation, Heparin-induced thrombocytopenia, Fibrinogen, Protein C, The Queen's Award for Enterprise: Innovation (Technology) (2011), Bleeding time, Factor, Activated protein C resistance, Factor X, Prothrombin time, Factor VIII, Prekallikrein, Factor V, Antithrombin, POC, Protein S, Factor XII, Factor XI, Fine chemical, Plasmin

The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.
  • New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation.
  • Coagulation testing will also become more standardized, offering opportunities for quality control products and services.

New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Blood, Branches of biology, Coagulation system, Anatomy, Haemophilia, Recombinant proteins, Factor VII, International Society on Thrombosis and Haemostasis, Haemophilia A, Factor V, Emicizumab, Recombinant factor VIIa, Hemlibra, hemophilia A, Genentech in hemophilia, Genentech, HEMLIBRA, HEMOPHILIA A, GENENTECH IN HEMOPHILIA, GENENTECH

The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, July 17-21.

Key Points: 
  • The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, July 17-21.
  • These results provide further confidence in Hemlibras favorable safety profile in people with hemophilia A with factor VIII inhibitors, who have historically faced significant treatment challenges.
  • Nearly one in three people with severe hemophilia A develop factor VIII inhibitors, antibodies that bind to and block the efficacy of replacement factor VIII.
  • Hemlibra has been approved in more than 100 countries worldwide for the treatment of people with hemophilia A with factor VIII inhibitors.

GenScript ProBio and Neoletix signed a letter of intent on clinical and commercial production of recombinant human coagulation factor VIII

Retrieved on: 
Tuesday, June 1, 2021
Branches of biology, Coagulation system, Biology, Life sciences, Recombinant DNA, Factor VII, Coagulation

NANJING, China, June 1, 2021 /PRNewswire/ -- On June 1st 2021, GenScript ProBio and Neoletix (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as Neoletix) signed a letter of intent on cooperation for clinical and commercial production of human coagulation factor VIII.

Key Points: 
  • NANJING, China, June 1, 2021 /PRNewswire/ -- On June 1st 2021, GenScript ProBio and Neoletix (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as Neoletix) signed a letter of intent on cooperation for clinical and commercial production of human coagulation factor VIII.
  • GenScript ProBio successfully completed delivery of 200L GMP recombinant coagulation factor VIII (rhFVIII) for Neoletix on February 7, 2021.
  • GenScript ProBio successfully delivered the project with its internationally-recognized development platform and rich experience in difficult molecule development, such as recombinant proteins and tri-antibodies, and achieved further cooperation intent on clinical production and commercial production.
  • GenScript ProBio's world-renowned GMP production capability can provide large-scale production services for biological macromolecules from clinical phase through commercialization.

Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Coagulation system, Health sciences, Pharmacy, Body fluids, Glycoproteins, Recombinant factor VIIa, Factor VII, Coagulation, Glanzmann's thrombasthenia, Haemophilia A, Pharmacodynamics

MarzAA is a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa).

Key Points: 
  • MarzAA is a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa).
  • MAA-202 is a Phase 1/2 open-label study designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and efficacy of SQ MarzAA for treatment of bleeding in FVII deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients receiving Hemlibra\xc2\xae prophylaxis.
  • "We look forward to providing updates on the MarzAA clinical development program, including reporting interim data from MAA-202 later this year.
  • The Company does not assume any obligation to update any forward-looking statements, except as required by law.\n'

Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit

Retrieved on: 
Thursday, May 13, 2021
Coagulation system, Branches of biology, Factor VII, Recombinant factor VIIa, Coagulation, Forward-looking statement, Protease

b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Truist Securities Life Sciences Summit at 1:00 pm ET on Monday, May 17, 2021.\nTo access a live webcast of the presentation, please click https://kvgo.com/life-sciences-summit/catalyst-biosciences-may-2021 .

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Truist Securities Life Sciences Summit at 1:00 pm ET on Monday, May 17, 2021.\nTo access a live webcast of the presentation, please click https://kvgo.com/life-sciences-summit/catalyst-biosciences-may-2021 .
  • Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders.
  • Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements.
  • The Company does not assume any obligation to update any forward-looking statements, except as required by law.\n'

Global Hemophilia A Market to 2030 - Insights, Epidemiology and Forecast - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
General Health, Pharmaceutical, Health, Coagulation system, Branches of biology, Proteins, Recombinant proteins, Cofactors, Factor VIII, Factor VII, Recombinant factor VIIa, Haemophilia

The "Hemophilia A - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemophilia A - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Hemophilia A market report provides current treatment practices, emerging drugs, Hemophilia A market share of the individual therapies, current and forecasted Hemophilia A market size from 2018 to 2030 segmented by seven major markets.
  • The current market for Hemophilia A includes Recombinant factor VIII (short and long-acting), Plasma-derived products, bypassing agents, bi-specific antibody, and a few others.
  • To understand the future market competition in the Hemophilia A market and Insightful review of the key market drivers and barriers.

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Retrieved on: 
Thursday, March 4, 2021
Coagulation system, Blood, Anatomy, Body fluids, Coagulation, Factor VIII, Factor VII, Haemophilia, Factor V, Jeanne Lusher

Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.

Key Points: 
  • Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
  • The Hemophilia Enzycard, the first product using Enzyre's proprietary Enzypad platform technology, can be used to determine the coagulation status of patients with hemophilia, a rare genetic disorder that affects an estimated 400,000 people worldwide.
  • [1] Those with hemophilia lack sufficient blood-clotting proteins, for example factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia.
  • Enzycard will enable patients to test in a home setting, immediately transferring coagulation status results to the patient's treating physician through a mobile phone app.

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Retrieved on: 
Thursday, March 4, 2021
Coagulation system, Blood, Anatomy, Body fluids, Coagulation, Factor VIII, Factor VII, Haemophilia, Factor V, Jeanne Lusher

Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.

Key Points: 
  • Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
  • The Hemophilia Enzycard, the first product using Enzyre's proprietary Enzypad platform technology, can be used to determine the coagulation status of patients with hemophilia, a rare genetic disorder that affects an estimated 400,000 people worldwide.
  • [1] Those with hemophilia lack sufficient blood-clotting proteins, for example factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia.
  • Enzycard will enable patients to test in a home setting, immediately transferring coagulation status results to the patient's treating physician through a mobile phone app.

LFB Announces that the European Medicines Agency (EMA) Has Accepted for Filing the Marketing Authorization Application for eptacog beta (activated), a Recombinant Coagulation Factor VIIa

Retrieved on: 
Monday, March 1, 2021
Biotechnology, Other Health, Hospitals, Health, Pharmaceutical, Coagulation system, Life sciences, Branches of biology, Anatomy, Peripheral membrane proteins, Biotechnology, Acute-phase proteins, Factor VII, Biopharmaceutical, Recombinant factor VIIa, Coagulation, Thrombin

LFB today announced that the European Medicines Agency (EMA), the European regulatory authority, has accepted for filing the Marketing Authorization Application for eptacog beta, a recombinant coagulation Factor VIIa (rFVIIa).

Key Points: 
  • LFB today announced that the European Medicines Agency (EMA), the European regulatory authority, has accepted for filing the Marketing Authorization Application for eptacog beta, a recombinant coagulation Factor VIIa (rFVIIa).
  • An exclusive license for the commercialization of SEVENFACT in the USA has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.
  • Created in France in 1994, LFB is today one of the leading European companies providing plasma-derived and recombinant medicinal products to healthcare professionals.
  • Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human FVIIa) and emicizumab in congenital haemophilia A plasma.